EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Rapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective

Knut Sandok Wigestrand, Santosh Gupta, Kulbhushan Sharma, Goran Petrovski

Journal of Clinical & Translational Ophthalmology · 2024

DOI: 10.3390/jcto2030009 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Clinical & Translational Ophthalmology, 2024. Verfasst von Knut Sandok Wigestrand und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pre-clinical studies related to the use of rapamycin (Sirolimus®), a mammalian target of rapamycin (mTOR) inhibitors, for age-related macular degeneration (AMD) have shown improved therapeutic outcomes. However, knowledge of its dose–effect relationship in humans with AMD has been limited and requires further investigation.

Objective

The aim of this study is to assess the safety and efficacy of Sirolimus® for treatment of AMD in humans and determine the dose range for its application in the eye.

Methods

A systematic literature review was conducted following the PRISMA guidelines. The MEDLINE, Embase, CINAHL, Scopus and Cochrane Central Registry of Controlled Trials databases were searched for original clinical studies examining the effects of Sirolimus® on outcomes linked to AMD in humans. This review has been registered in the PROSPERO database.

Results

Only four studies were found to satisfy the inclusion and exclusion criteria and were analyzed in this systematic review in a narrative way. The dose range of rapamycin in the limited number of studies appears to be toxic to the retina.

Conclusion

Future studies should focus on establishing the optimal low-dose range of Sirolimus® that effectively induces autophagy without causing retinal toxicity, as current data indicate a potential therapeutic window that remains underexplored. Specifically, longitudinal, controlled studies with larger, heterogeneous patient populations are necessary to determine the precise dosing that balances efficacy and safety in treating AMD.

Zitieren

APA

Wigestrand, K. S., Gupta, S., Sharma, K., & Petrovski, G. (2024). Rapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective. Journal of Clinical & Translational Ophthalmology. https://doi.org/10.3390/jcto2030009

Vancouver

Wigestrand KS, Gupta S, Sharma K, Petrovski G. Rapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective. Journal of Clinical & Translational Ophthalmology. 2024. doi:10.3390/jcto2030009

BibTeX
@article{Wigestrand2024,
  author = {Wigestrand, Knut Sandok and Gupta, Santosh and Sharma, Kulbhushan and Petrovski, Goran},
  title = {Rapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective},
  journal = {Journal of Clinical & Translational Ophthalmology},
  year = {2024},
  doi = {10.3390/jcto2030009}
}
Kostenlos starten →